How much cash does SELLAS Life Sciences Group, Inc. generate?

SELLAS Life Sciences Group, Inc. (SLS) generated -$28.2M in operating cash flow over the trailing twelve months.

Where does SELLAS Life Sciences Group, Inc.'s cash flow data come from?

Every line is extracted from SELLAS Life Sciences Group, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

SELLAS Life Sciences Group, Inc. SLS Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$29.46M-8.6%	-$26.86M+13.0%	-$25.94M+19.6%	-$26.26M+23.8%	-$27.13M+24.2%
Stock-based compensation	$2.25M+41.2%	$1.96M+25.1%	$1.88M+11.5%	$1.76M-4.9%	$1.59M-21.5%
Change in accounts payable	——	——	-$2.31M-879%	-$3.05M-214%	-$3.67M-184%
Change in accrued liabilities	——	——	——	——	——
Change in other assets	——	——	——	——	——
Non-cash operating lease expense	$603K+5.8%	$597K+6.4%	$591K+9.2%	$581K+10.5%	$570K+4.4%
Change in operating lease liabilities	-$635K-13.4%	-$635K-19.1%	-$611K-15.3%	-$586K-11.4%	-$560K-0.5%
Net cash from operating activities	-$28.17M+16.5%	-$28.39M+19.8%	-$30.62M+7.4%	-$31.36M+2.5%	-$33.71M-12.2%
Proceeds from issuance of common stock	——	——	——	——	$48K—
Taxes paid for net share settlement	——	$527K+723%	$411.25K+638%	$295.5K+522%	$179.75K+358%
Net cash from financing activities	$106.87M+145%	$86.3M+84.6%	$53.91M+7.5%	$47.51M+55.8%	$43.69M+45.2%
Net increase (decrease) in cash	$81.8M—	$61.01M—	——	——	——
Operating lease liabilities	-$635K-13.4%	-$635K-19.1%	-$611K-15.3%	-$586K-11.4%	-$560K-0.5%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Operating lease right-of-use asset amortization	$603K+5.8%	$597K+6.4%	$591K+9.2%	$581K+10.5%	$570K+4.4%
Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs	——	——	——	$42.61M—	$42.65M—
Proceeds from issuance of common stock relating to employee stock plans	——	——	——	——	——
Proceeds From Warrant Exercises	$56.2M+5,442%	$12.62M+2,153%	$8.71M+1,421%	$4.87M+1,065%	$1.01M+1,510%
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction	——	——	-$30K-117%	-$55K-135%	-$83K-147%
Increase Decrease In Operating Lease Liability	-$635K-13.4%	-$635K-19.1%	-$611K-15.3%	-$586K-11.4%	-$560K-0.5%
Proceeds From Interest Received	$2.01M+150%	$1.41M+123%	$995K+102%	$924K+153%	$803K+90.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does SELLAS Life Sciences Group, Inc. generate?: SELLAS Life Sciences Group, Inc. (SLS) generated -$28.2M in operating cash flow over the trailing twelve months.
Where does SELLAS Life Sciences Group, Inc.'s cash flow data come from?: Every line is extracted from SELLAS Life Sciences Group, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.